ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Works in Dermatology · Genetic & rare · GI & liver · Hematology · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Renal & urogenital · Respiratory · Women's health

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) is a clinical trial sponsor. It has 1 active clinical trial with 190 planned participants, across 11 therapeutic areas. Since 2021 it has completed 1 trial and stopped 2 early.

Trial track record · since 2021

1Active trials190 planned participants
1Completed3 with results posted
2Stopped earlyterminated, withdrawn or suspended

Pipeline · 1 active trial

StageTrialStatus

Questions about ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-06-12.

Approve Suite is not affiliated with ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA).

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.